Hyperhidrosis, a disorder characterized by excessive sweating, can be focal or generalized. The severity of hyperhidrosis can vary from slight wetness to severe wet and can cause significant damage to the quality of life, which includes limitations in social and work relationships, leisure, and physical activities. It can even impact mental and emotional health. Hyperhidrosis can occur due to medical conditions such as diabetes, injury, such as head trauma caused by an accident, menopause, obesity, and overactive thyroid (hyperthyroidism).
It affects multiple body parts, most frequently the armpits, palms, face or soles. Nearly 3% of the population, mostly individuals aged between 25 and 64 years, suffer from hyperhidrosis. Hyperhidrosis brings a significant social and psychological burden, as it hampers daily activities. However, individuals suffering from this disorder rarely seek medical help, as several patients are unaware that they are suffering from a treatable medical disorder. Primary recognition and managing of hyperhidrosis can significantly recover a patient’s quality of life. There are several systemic, topical, surgical and nonsurgical treatments available with effectiveness rates ranging between 90% and 95%.
The global Hyperhidrosis Treatment Market can be segmented based on type, treatment, end user, and geography. Based on type, the hyperhidrosis market can be classified into generalized and focal. Generalized hyperhidrosis includes the complete body and is generally a part of the primary condition, most often an endocrine, infectious, or neurologic disorder. Focal hyperhidrosis is idiopathic, arising in healthy people. Based on treatment, the hyperhidrosis market can be segregated into topical treatments, Iontophoresis, Botulinum toxin A, surgical treatments, and systemic treatments. Topical treatment includes aluminum salts, which is the most common over-the-counter ingredient in antiperspirants that are utilized to treat focal hyperhidrosis.
Request to View Brochure of Report –
Moreover, aldehyde agents such as glutaraldehyde and formaldehyde are also employed to treat hyperhidrosis as topical treatments. Iontophoresis is the diffusion of ions into the skin by means of an electrical current. Botulinum toxin A is used to treat hyperhidrosis, which is a form of neurotoxin produced by the anaerobic bacterium Clostridium botulinum. Surgical treatments comprise endoscopic thoracic sympathectomy that terminates the sympathetic ganglia by clamping, excision, ablation, or transection with laser or cautery. The systemic treatment includes anticholinergic agents that inhibit synaptic acetylcholine, they interfere with neuroglandular signaling. Based on distribution channel, the global market for hyperhidrosis can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
In terms of geography, the hyperhidrosis market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Furthermore, the North America hyperhidrosis market can be segmented into U.S., and Canada. The Europe hyperhidrosis market can be segregated into U.K., Germany, France, Italy, Spain, and Rest of Europe. The Asia Pacific Hyperhidrosis market can be further segmented into Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific.